Last edition
News about "clinical-stage biopharmaceutical company"
Vivani Medical has entered into an agreement with Novo Nordisk to evaluate NPM-139, its ultra long-acting semaglutide implant for chronic weight management. The implant aims to offer a convenient once- or twice-yearly treatment option, with Phase 1 clinical trials expected to commence in mid-2026.
Clinical-stage Biopharmaceutical Company | 09/07/2026 | By News Bureau
Vyome Secures China Patent for Besifloxacin Topical Gel in Inflammatory Acne Treatment
Vyome Holdings has secured a Chinese patent for its proprietary besifloxacin topical gel programme, strengthening intellectual property protection for inflammatory acne treatment and expanding future commercial opportunities in one of the world's largest dermatology markets.
Clinical-stage Biopharmaceutical Company | 04/07/2026 | By News Bureau
BioVersys AG receives US Food and Drug Administration nod to include US patients in Phase III BV100 trial targeting drug-resistant pneumonia, marking progress in combating deadly hospital infections globally.
Clinical-stage Biopharmaceutical Company | 18/03/2026 | By News Bureau | 140
Aisa Pharma presented Phase II RECONNOITER trial results showing AISA-021 improved attack-free days and reduced duration of Raynaud’s attacks in systemic sclerosis patients at the World Systemic Sclerosis Congress.
Clinical-stage Biopharmaceutical Company | 10/03/2026 | By News Bureau | 127
Rondo Therapeutics Begins First-in-Human Trial of Novel CD28 - Nectin-4 Bispecific for Solid Tumours
Rondo Therapeutics, a clinical-stage biopharmaceutical company developing next-generation T-cell engaging bispecific antibodies for solid tumours, has begun dosing patients in its phase 1/1b clinical trial of RNDO-564.
Clinical-stage Biopharmaceutical Company | 07/12/2025 | By Darshana | 334
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy